Navigation Links
The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
Date:8/19/2007

Phase 2 Study to Explore the Efficacy of Novel Proteasome Inhibitor in

Patients with Relapsed and Refractory Multiple Myeloma

SOUTH SAN FRANCISCO, Calif. and NORWALK, Conn., Aug. 15 /PRNewswire/ -- The Multiple Myeloma Research Consortium (MMRC) and Proteolix, Inc. today announced the enrollment of the first patient in a multi-center Phase 2 clinical trial to study Proteolix's potent and selective proteasome inhibitor, carfilzomib (PR-171), in patients with relapsed and refractory multiple myeloma. Ten MMRC Member Institutions will participate in the study, under the MMRC leadership of Melissa Alsina, MD, H. Lee Moffitt Cancer Center & Research Institute. The nine additional sites are the City of Hope, Emory University, Cancer Center at Hackensack University Medical Center, Mayo Clinic, Princess Margaret/University Health Network, Saint Vincent's Comprehensive Cancer Center, University of Michigan, and Washington University.

The MMRC is the only research model of its kind that brings together 13 leading academic institutions to accelerate the development of novel and combination treatments for multiple myeloma, an incurable cancer of the plasma cell.

"Proteasome inhibitors are an important class of drugs for the treatment of multiple myeloma and we are proud to work with Proteolix to advance the clinical development of carfilzomib," said Kathy Giusti, Founder and Chief Executive Officer of the MMRC. "This trial and the others the MMRC are facilitating underscore our commitment to bring better, more effective treatments to myeloma patients as quickly as possible."

The trial will evaluate the overall response rate (ORR) for two cycles of carfilzomib in patients with multiple myeloma who have previously received specific FDA-approved therapies, have relapsed after two or more of such therapies, and are refractory to the most recently received therapy. Secondary objectives of this study include safety and tolerability, clinica
'/>"/>

SOURCE Proteolix

Copyright©2007 PR Newswire.

Page: 1 2 3 4

Related medicine technology :

1. Keryx Biopharmaceuticals, Inc. Announces Positive Phase I and Phase II Data on KRX-0401 in Patients with Relapsed/Refractory Multiple Myeloma and Waldenstroms Macroglobulinemia
2. Velcade (Bortezomib) for Injection Based Therapies Produced Complete Remission Rates as High as 54 Percent in Patients With Previously Treated Multiple Myeloma
3. Velcade (bortezomib) for Injection Based Therapies Achieved Survival Rates as High as 100 Percent in Newly Diagnosed Multiple Myeloma Patients
4. Gentiums Defibrotide Seen as Active in Multiple Myeloma
5. ACE-011 Improves Multiple Myeloma Bone Disease in a Preclinical Model
6. New Data from Multiple Studies Show Galvus Delivers Consistent and Robust Blood Sugar Control in Patients with Type 2 Diabetes
7. CytRx Announces Clinical Results from Its Rising Multiple Dose Trial with Arimoclomol for ALS
8. Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Extension Trial with Tovaxin for Multiple Sclerosis
9. Velcade (bortezomib) for Injection Survival Data in Front-Line Multiple Myeloma Patients to be Featured at 11th International Myeloma Workshop
10. New Research Demonstrates Broad Efficacy of Azixa (MPC-6827) Against Multiple Tumor Types and in Drug Resistant Cell Lines
11. Orchestra Therapeutics Announces New Phase II Clinical Data on NeuroVax Demonstrating Marked Expansion of Regulatory T Cell Populations in Patients With Multiple Sclerosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... Sept. 19, 2014  PCI is pleased to ... Biotec is a leading provider of Clinical Trial ... Bridgend, Wales in the ... significantly expands PCI,s presence in the UK/EU to ... adding packaging, storage and distribution capacity, as well ...
(Date:9/18/2014)... 18, 2014  Low T Center endorses the ... Hyattsville, Maryland earlier this ... proper patient population for testosterone therapy (TRT), as ... with TRT. Examining recent claims from studies that TRT ... epidemiological studies do not provide convincing evidence that ...
(Date:9/18/2014)... , September 18, 2014 ... Markets ( http://www.researchandmarkets.com/research/f9nkkh/sugar_alcohols ) has announced the addition ... Business Report"  report to their offering.  ... analyzes the worldwide markets for Sugar Alcohols ... Segments: Food & Confectionery, Pharmaceuticals, Cosmetics, Oral-Care ...
Breaking Medicine Technology:PCI Announces Acquisition Of Biotec 2PCI Announces Acquisition Of Biotec 3PCI Announces Acquisition Of Biotec 4PCI Announces Acquisition Of Biotec 5PCI Announces Acquisition Of Biotec 6Low T Center Endorses The Joint FDA Committee Meeting on Testosterone 2Sugar Alcohols - Global Strategic Business Report 201 2Sugar Alcohols - Global Strategic Business Report 201 3
... Vascular Disrupting Agent and,Tubulin Inhibitor , SALT ... Inc.,(NASDAQ: MYGN) (<a target="_blank" href=,"http://www.myriad.com/">www.myriad.com ) announced ... mode of action of its,investigational new drug, ... annual meeting of the American Association for ...
... 18, 2007 - Gemin,X today announced the presentation ... lead compound, GX15-070 (obatoclax), in infant,acute lymphoblastic leukemia ... at the Annual Meeting of the American Association,for ... potent single agent activity against ALL blast cells,and ...
Cached Medicine Technology:Myriad Genetics Presents Azixa's Mode of Action at AACR 2Myriad Genetics Presents Azixa's Mode of Action at AACR 3Gemin X Presents Positive Preclinical Data of GX15-070 in Infant,ALL at AACR Meeting 2Gemin X Presents Positive Preclinical Data of GX15-070 in Infant,ALL at AACR Meeting 3
(Date:9/19/2014)... New York (PRWEB) September 19, 2014 ... & Game Building Platform . Earlier this month Appy Pie ... Powerful Tools for the Aspiring App Developer' by Yahoo . ... which allows people to develop beautiful applications within minutes and ... development, With advanced features and support for latest mobile operating ...
(Date:9/19/2014)... HealthDay Reporter THURSDAY, ... escalated the fight against antibiotic-resistant bacteria on Thursday, ordering ... deal with the threat. Obama signed an ... charged with crafting a national action plan for dealing ... treatable bacteria that have become resistant to standard antibiotics ...
(Date:9/19/2014)... 2014 ShopRite has launched its new ... with the 2014-2015 school year. The new program will ... eBoxTops and special donations throughout the year. , Customers ... registering their ShopRite Price Plus Card at shopriteformyschool.com can ... favorite school. By using their Price Plus Club Card ...
(Date:9/19/2014)... September 19, 2014 The Translational ... new ND® Infusion Catheter is being used ... , The study commenced on September 4th, 2014 at ... of the new catheter demonstrated a number of advancements ... stem cells. “We are at the forefront of revolutionizing ...
(Date:9/19/2014)... QueenBeeTickets.com has the largest ticket inventory that online ... set to begin on January 21 of 2015, discount John ... secure website. , Click Here to view the ... , The Plain Spoken Tour has recently been announced, and ... a show coming to their local area. Presales have been ...
Breaking Medicine News(10 mins):Health News:Business Insider Australia Rates Appy Pie as a top App & Game Building Platform 2Health News:Obama Calls for National Plan to Fight Antibiotic Resistance 2Health News:ShopRite to Donate Up to $1 Million to Local Schools 2Health News:First-in-man procedure utilizes a new method of stem cell delivery 2Health News:First-in-man procedure utilizes a new method of stem cell delivery 3Health News:John Mellencamp Plain Spoken Tour Tickets: QueenBeeTickets.com Delights Customers with Discount Tickets for Mellencamp’s 80-City 2015 Concert Tour with Carlene Carter 2
... disease characterized by difficultly in breathing and the ... in these patients. Earlier research has shown that ... and endurance of respiratory muscles of COPD patients, ... found that this intense training// is difficult for ...
... of Texas has found a gene mutation in people with ... too much calcium. They reported on six gene mutations which ... much calcium absorption - a condition known as absorptive hypercalciuria ... a greater risk// for osteoporosis because of deficiencies in the ...
... hospitals to overcome illness. However, very often, patients land ... infections that they contract during their stay. Sanjay Saint, ... born infections are common, costly and harmful, but they ... which can be prevented by new and simple// changes. ...
... Chronic Obstructive Pulmonary Disease - including chronic bronchitis and ... blockage of the bronchial tubes. Asthma is a chronic ... resulting in episodes of airflow obstruction, which has been ... death and affects nearly 16 million people in the ...
... in the United States have found that the practice ... the past 14 years. However, they suggested that patients ... Helicobacter Pylori(H.Pylori) infection rather than receiving treatment for the ... more appropriate option// than empiric treatment in patients with ...
... with heart disease has shown that doctors are under-using ... these women even though the medications have been shown ... Though this study did not look at how often ... shown that men and women alike are under-treated for ...
Cached Medicine News:Health News:Adult COPD or asthma could be effectively treated with Xopenex 2Health News:Heart disease in women being under-treated 2
... Utilized for capsulotomies, nucleus ... Formed (bent) cystitomes are angled ... of the lens, providing easier ... while reducing the potential for ...
23 gauge thin wall irrigation. 25 gauge thin wall aspiration. Angled 30 degree shaft 8 mm from tip to bend. Irrigation tip set 0.5 mm behind aspiration tip. Dual hub construction. Polished finish. Ov...
U tip irrigation-aspiration cannual designed for manual removal of 12 oclock cortex. 23 gauge thin wall irrigation and aspiration lines for maximum aspiration capabilities. Polished finish. Overall l...
This specially designed 23 gauge spoon-shaped cannula is connected to a balanced salt solution bottle and with a low-flow of fluid, is designed to allow a controlled cleaning of the stromal interface...
Medicine Products: